Successful experience of tofacitinib treatment in patients with Fibrodysplasia Ossificans Progressiva-Reference-Cited by-同舟云学术

Successful experience of tofacitinib treatment in patients with Fibrodysplasia Ossificans Progressiva

Published:2023-08-29 Issue:1 Volume:21 Page:
ISSN:1546-0096
Container-title:Pediatric Rheumatology
language:en
Short-container-title:Pediatr Rheumatol

Author:

Nikishina Irina P.^ORCID,Arsenyeva Svetlana V.^ORCID,Matkava Valeria G.^ORCID,Arefieva Alia N.^ORCID,Kaleda Mariya I.^ORCID,Smirnov Alexandr V.^ORCID,Blank Leonid M.^ORCID,Kostik Mikhail M.^ORCID

Abstract

AbstractFibrodysplasia ossificans progressive (FOP) is an ultra-rare genetic disorder that is caused by a mutation in the ACVR1 gene and provokes severe heterotopic ossification. Since flares of the disease are associated with inflammation, it is assumed that JAK inhibitors can control active FOP due to blocking multiple signaling pathways.

Publisher

Springer Science and Business Media LLC

Subject

Immunology and Allergy,Rheumatology,Pediatrics, Perinatology and Child Health

Link

https://link.springer.com/content/pdf/10.1186/s12969-023-00856-1.pdf

Reference20 articles.

1. Kaplan FS, Le Merrer M, Glaser DL, Pignolo RJ, Goldsby RE, Kitterman JA, et al. Fibrodysplasia ossificans progressiva. Best Pract Res Clin Rheumatol. 2008;22(1):191–205. https://doi.org/10.1016/j.berh.2007.11.007.

2. Barruet E, Morales BM, Cain CJ, Ton AN, Wentworth KL, Chan TV, Moody TA, Haks MC, Ottenhoff TH, Hellman J, Nakamura MC, Hsiao EC. NF-κB/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification. JCI Insight 2018 Nov 15;3(22):e122958. doi: https://doi.org/10.1172/jci.insight.122958.

3. Barruet E, Morales BM, Lwin W, White MP, Theodoris CV, Kim H, Urrutia A, Wong SA, Srivastava D, Hsiao EC. The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling. Stem Cell Res Ther 2016 Aug 17;7(1):115. doi: https://doi.org/10.1186/s13287-016-0372-6. PMID: 27530160; PMCID: PMC4988052.

4. Nikishina I, Arsenyeva S, Matkava V, Arefieva A, Pachkoria T. Unexpected clinical findings as evidence of the relation of Fibrodysplasia ossificans progressiva to axial spondyloarthritis. Clin Exp Rheumatol. 2021;39:1149–263. P177.

5. Pignolo RJ, McCarrick-Walmsley R, Wang H, Qiu S, Hunter J, Barr S, He K, Zhang H, Kaplan FS. Plasma-soluble biomarkers for Fibrodysplasia Ossificans Progressiva (FOP) reflect Acute and Chronic Inflammatory States. J Bone Miner Res 2022 Mar;37(3):475–83. doi: https://doi.org/10.1002/jbmr.4492. Epub 2022 Jan 24.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fibrodysplasia ossificans progressiva (clinical observation with a brief review of the literature);N.N. Priorov Journal of Traumatology and Orthopedics;2024-07-04

2. Interleukin 1 receptor antagonist as biomarker for disease flares in fibrodysplasia ossificans progressiva;Bone;2024-07

3. Long-term use of interleukin-1 inhibitors reduce flare activity in patients with fibrodysplasia ossificans progressiva;Rheumatology;2024-05-11

4. Immunologic Aspects in Fibrodysplasia Ossificans Progressiva;Biomolecules;2024-03-16

5. Intersections of Fibrodysplasia Ossificans Progressiva and Traumatic Heterotopic Ossification;Biomolecules;2024-03-14